# NDI-219216

Source: https://onco.cc/drugs/ndi-219216/  
OnCo record `ndi-219216` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NDI-219216 is an experimental small-molecule drug from Nimbus Wadjet in phase 2 trials, aimed at WRN helicase (MSI-high cancers).

## Summary

NDI-219216 is a small-molecule drug developed by Nimbus Wadjet. Its target is WRN helicase (MSI-high cancers) (the sponsor names WRN helicase). The sponsor states: NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach. ClinicalTrials.gov describes the intervention as: NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06898450, plans to enrol 134 participants with primary completion expected 2031-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach.

## Sources

- ClinicalTrials.gov: trials of NDI-219216: https://clinicaltrials.gov/search?intr=NDI-219216
- Sponsor pipeline page: https://nimbustx.com/pipeline/

## Connected records

- targets: [WRN helicase (MSI-high cancers)](https://onco.cc/targets/wrn/)
- companies: [Nimbus Therapeutics](https://onco.cc/companies/nimbus-therapeutics/)
- trials: [A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct06898450/)

---
JSON: https://onco.cc/api/v1/entities/ndi-219216.json